US › Healthcare

Minerva Neurosciences Inc (NERV)

US · Healthcare · Biotechnology

$4.04+1.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-125.4M
Profit YoY
-3241.5%
EPS
$-0.17
EPS estimate
$-0.14

EPS came in at -0.17 against a street estimate of -0.14 — a miss of 23.2%.

Key statistics

Market cap
$185.4M
Forward P/E
11.2
P/B
2.68
Book value
$-5.79
EPS (TTM)
$-37.03
52-week high
$8.80
52-week low
$1.76
50-day MA
$4.62
200-day MA
$5.00
Beta
-0.18

Analyst view

Analysts rate Minerva Neurosciences Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $9.50.

Shareholding

Insiders
3.34%
Institutions
97.93%

Largest institutional holders

FundStake
Federated Hermes Inc11.66%
Vivo Capital, LLC9.86%
HHG PLC9.79%
Balyasny Asset Management LLC9.71%
Logos Global Management LP7.33%
Farallon Capital Management, L.L.C.5.39%
Foresite Capital Management VI LLC4.53%
Vanguard Capital Management, LLC4.21%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Minerva Neurosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.